255 related articles for article (PubMed ID: 22661948)
61. Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer.
Helland T; Alsomairy S; Lin C; Søiland H; Mellgren G; Hertz DL
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33805613
[TBL] [Abstract][Full Text] [Related]
62. Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction.
Parihar V; Rogers A; Blain AM; Zacharias SRK; Patterson LL; Siyam MA
J Pharm Pract; 2022 Apr; 35(2):322-326. PubMed ID: 33191836
[TBL] [Abstract][Full Text] [Related]
63. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.
Saladores P; Mürdter T; Eccles D; Chowbay B; Zgheib NK; Winter S; Ganchev B; Eccles B; Gerty S; Tfayli A; Lim JS; Yap YS; Ng RC; Wong NS; Dent R; Habbal MZ; Schaeffeler E; Eichelbaum M; Schroth W; Schwab M; Brauch H
Pharmacogenomics J; 2015 Feb; 15(1):84-94. PubMed ID: 25091503
[TBL] [Abstract][Full Text] [Related]
64. Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer.
Woo HI; Lee SK; Kim J; Kim SW; Yu J; Bae SY; Lee JE; Nam SJ; Lee SY
Oncotarget; 2017 Nov; 8(59):100296-100311. PubMed ID: 29245979
[TBL] [Abstract][Full Text] [Related]
65. Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry.
Jaremko M; Kasai Y; Barginear MF; Raptis G; Desnick RJ; Yu C
Anal Chem; 2010 Dec; 82(24):10186-93. PubMed ID: 21086978
[TBL] [Abstract][Full Text] [Related]
66. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
Kneller LA; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
[TBL] [Abstract][Full Text] [Related]
67. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.
Henderson SL; Teft WA; Kim RB
BMC Cancer; 2016 May; 16():304. PubMed ID: 27169677
[TBL] [Abstract][Full Text] [Related]
68. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
69. [Advances in the research of pharmacogenomics of tamoxifen].
Xiong W; Zhao JJ; Wang L; Jiang XH; Tao XQ
Yao Xue Xue Bao; 2016 Sep; 51(9):1356-67. PubMed ID: 29924509
[TBL] [Abstract][Full Text] [Related]
70. Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics.
Pang H; Zhang G; Yan N; Lang J; Liang Y; Xu X; Cui Y; Wu X; Li X; Shan M; Wang X; Meng X; Liu J; Tian G; Cai L; Yuan D; Wang X
Front Oncol; 2021; 11():738222. PubMed ID: 34868931
[TBL] [Abstract][Full Text] [Related]
71. Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio.
Lee CI; Low SK; Maldonado R; Fox P; Balakrishnar B; Coulter S; de Bruijn P; Koolen SLW; Gao B; Lynch J; Zdenkowski N; Hui R; Liddle C; Mathijssen RHJ; Wilcken N; Wong M; Gurney H
Breast; 2020 Dec; 54():229-234. PubMed ID: 33161337
[TBL] [Abstract][Full Text] [Related]
72. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
73. Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites.
Chen Y; Marcath LA; Eliassen FM; Lende TH; Soiland H; Mellgren G; Helland T; Hertz DL
J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34199712
[TBL] [Abstract][Full Text] [Related]
74. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract][Full Text] [Related]
75. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
[TBL] [Abstract][Full Text] [Related]
76. Pharmacogenomics of endocrine therapy in breast cancer.
Weinshilboum R
Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
[TBL] [Abstract][Full Text] [Related]
77. Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen.
Nakamura T; Toshimoto K; Lee W; Imamura CK; Tanigawara Y; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Jul; 7(7):474-482. PubMed ID: 29920987
[TBL] [Abstract][Full Text] [Related]
78. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.
Hwang GS; Bhat R; Crutchley RD; Trivedi MV
Pharmacogenomics J; 2018 Apr; 18(2):201-208. PubMed ID: 28762370
[TBL] [Abstract][Full Text] [Related]
79. CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen.
Antunes MV; de Oliveira V; Raymundo S; Staudt DE; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Mathy G; Wallemacq P; Linden R; Schwartsmann G; Haufroid V
Pharmacogenomics; 2015; 16(6):601-17. PubMed ID: 25893704
[TBL] [Abstract][Full Text] [Related]
80. Pharmacogenomics of tamoxifen therapy.
Brauch H; Mürdter TE; Eichelbaum M; Schwab M
Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
